Table 2 Diagnostic accuracy of ten ACPAs (presented in alphabetical order), anti-CCP2 antibodies, anti-CarP antibodies and RF isotypes, analysed separately and in combination with the three RF isotypes, for RA development in pre-symptomatic individuals

CCP-2

29.6 (26.08–33.39)

20.26 (10.58–38.83)

50.7 (12.4–207.5)

30.2 (7.3–124.9)

67.6 (16.6–275.9)

CEP-1

23.9 (20.64–27.51)

4.75 (3.14–7.2)

19.6 (7.1–54.4)

13.3 (4.7–37.3)

48.1 (11.7–197.4)

CitC1^III

12.71 (10.26–15.66)

3.77 (2.22–6.4)

36.9 (5.0–271.5)^b

25.1 (3.4–186.9)

45.7 (6.3–333.6)

Fibα_563–583

7.63 (5.74–10.08)

1.65 (0.99–2.78)

21.7 (2.9–162)

11.8 (1.5–91.7)

13.9 (3.3–59.2)

Fibα_580–600

6.95 (5.16–9.32)

1.05 (0.65–1.7)

6.2 (1.8–21.5)

6.3 (1.8–21.7)

5.2 (1.5–18.3)

Fibβ_36–52

22.54 (19.36–26.1)

3.98 (2.66–5.95)

17.5 (6.3–48.6)

15 (4.6–49)

45.2 (11–185.7)

Fibβ_62–81a

8.64 (6.63–11.22)

2.77 (1.56–4.92)

17.5 (2.3–131.4)

9.1 (1.1–72.8)

18.1 (2.4–135.8)

Fibβ_62–81b

13.39 (10.88–16.4)

9.2 (4.4–19.24)

42.6 (5.8–311.7)^b

24.8 (3.3–183.9)^b

50.2 (6.9–366.2)^b

Filaggrin

21.86 (18.72–25.39)

9.39 (5.33–16.55)

22.9 (7.1–73.6)

48.4 (6.6–353.4)

37.9 (9.2–156)

Vim_2–17

5.59 (4–7.79)

1.31 (0.75–2.29)

7.6 (1.7–33.5)

10.1 (1.3–79.6)

13.6 (1.8–104.3)

Vim_60–75

9.49 (7.38–12.15)

1.93 (1.18–3.14)

8.1 (2.4–27.3)

9.1 (2.1–39.5)

9.3 (2.8–30.8)

CarP

13.78 (10.81–17.43)

5.83 (2.08–16.36)

12.9 (1.7–95.7)^b

10.6 (1.4–78.6)

16.2 (2.2–119.2)^b

IgA-RF

24.75 (21.46–28.37)

9.07 (5.5–14.96)^a

–

23.9 (7.4–76.7)

21.9 (8.8–54.6)

IgG-RF

17.56 (14.72–20.83)

5.89 (3.53–9.82)^a

23.9 (7.4–76.7)

–

34.5 (8.4–142.2)

IgM-RF

26.09 (22.73–29.76)

11.08 (6.64–18.5)^a

21.9 (8.8–54.6)

34.5 (8.4–142.2)

–